7498 Results (Page 42 of 300)
Pharmaceuticals Markets Research Reports
Mexico Infectious Disease Drugs Market Analysis
Mexico Infectious Disease Drugs Market valued at $1.78 Bn in 2023, projected to reach $2.43 Bn by 2030 with a 4.52% CAGR. The market is being driven by advancements in healthcare infrastructure, government initiatives, and rising awareness about infectious diseases. The market is dominated by key players like AbbVie Inc., Gilead Sciences, GlaxoSmithKline plc, Merck & Co., F. Hoffman-La Roche Ltd., Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, Novartis AG, Sanofi S.A., Bayer AG, and Astellas Pharma Inc.
Brazil Infectious Disease Drugs Market Analysis
Brazil Infectious Disease Drugs Market valued at $2.96 Bn in 2023, projected to reach $4.25 Bn by 2030 with a 5.27% CAGR. The market is expanding due to increased healthcare spending, technological advancements, and awareness and education initiatives. The market is dominated by key players like Hypera Pharma, EMS S.A., AbbVie Inc., Gilead Sciences, GlaxoSmithKline plc, Merck & Co., F. Hoffman-La Roche Ltd., Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, and Novartis AG.
UAE Infectious Disease Drugs Market Analysis
UAE Infectious Disease Drugs Market valued at $0.59 Bn in 2023, projected to reach $0.85 Bn by 2030 with a 5.27% CAGR. The market is being driven by the prevalence of infectious diseases, government initiatives, and rising healthcare expenditure. The market is dominated by key players like Hikma Pharmaceuticals, Julphar Gulf Pharmaceutical Industries, Neopharma, AbbVie Inc., Gilead Sciences, GlaxoSmithKline plc, Merck & Co., F. Hoffman-La Roche Ltd., Boehringer Ingelheim International GmbH, and Janssen Pharmaceuticals.
Saudi Arabia Infectious Disease Drugs Market Analysis
Saudi Arabia Infectious Disease Drugs Market valued at $2.02 Bn in 2023, projected to reach $2.99 Bn by 2030 with a 5.77% CAGR. The industry is growing as a result of government initiatives, improvements in healthcare infrastructure, and rising healthcare costs. The market is dominated by key players like SPIMACO, Tabuk Pharmaceuticals, AbbVie Inc., Gilead Sciences, GlaxoSmithKline plc, Merck & Co., F. Hoffman-La Roche Ltd., Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, and Novartis AG.
Canada Infectious Disease Drugs Market Analysis
Canada Infectious Disease Drugs Market valued at $9.5 Bn in 2023, projected to reach $12.73 Bn by 2030 with a 4.27% CAGR. The market is driven by factors such as rising rates of infectious diseases, technological developments in medication development, and expanding healthcare infrastructure and awareness. The market is dominated by key players like Gilead Sciences, AbbVie Inc., GlaxoSmithKline plc, Merck & Co., F. Hoffman-La Roche Ltd., Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, Novartis AG, Pfizer Inc., and Sanofi.
US Infectious Disease Drugs Market Analysis
US Infectious Disease Drugs Market valued at $49.87 Bn in 2023, projected to reach $58.36 Bn by 2030 with a 2.27% CAGR. The market is expanding due to the prevalence of infectious diseases, improvements in drug development, and an aging population. The market is dominated by key players like AbbVie Inc., Gilead Sciences, GlaxoSmithKline plc, Merck & Co., F. Hoffman-La Roche Ltd., Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, Novartis AG, Pfizer Inc., and Lupin Pharmaceuticals.
Vietnam Atopic Dermatitis Therapeutics Market Analysis
The Vietnam Atopic Dermatitis Therapeutics Market was valued at US $62 Mn in 2022, and is predicted to grow at (CAGR) of 9.03% from 2023 to 2030, to US $123 Mn by 2030. The key drivers of this industry include the increased burden of Atopic Dermatitis (AD), improving healthcare infrastructure, shifting patient preferences, and others. The industry is primarily dominated by players such as Sanofi, Pharmacity, Merck, AbbVie, Domesco, Novartis, and Johnson & Johnson, among others.
US Atopic Dermatitis Therapeutics Market Analysis
The US Atopic Dermatitis Therapeutics Market was valued at US $5.166 Bn in 2022, and is predicted to grow at (CAGR) of 6.8% from 2023 to 2030, to US $8.744 Bn by 2030. The key drivers of this industry include the rising prevalence of Atopic Dermatitis (AD), innovative drugs in the pipeline and evolving healthcare landscape. The industry is primarily dominated by players such as Sanofi, AbbVie, Pfizer, Regeneron, Eli Lilly, Astellas among others.
UK Atopic Dermatitis Therapeutics Market Analysis
The UK Atopic Dermatitis Therapeutics Market was valued at US $320 Mn in 2022, and is predicted to grow at (CAGR) of 6.8% from 2023 to 2030, to US $541 Mn by 2030. The key drivers of this industry include the rising prevalence of Atopic Dermatitis (AD), evolving treatment landscape of the industry, and high medical unmet needs and diagnoses. The industry is primarily dominated by players such as Pfizer, Astellas, Novartis, Galderma, AbbVie, Anacor, Meda, and Allergan, among others.
UAE Atopic Dermatitis Therapeutics Market Analysis
The UAE Atopic Dermatitis Therapeutics Market was valued at US $62 Mn in 2022, and is predicted to grow at (CAGR) of 9.8% from 2023 to 2030, to US $130 Mn by 2030. The key drivers of this industry include the upward trend in prevalence of Atopic Dermatitis (AD), supportive government policies, and shifting treatment preferences. The industry is primarily dominated by players such as Sanofi, AbbVie, Pfizer, Bayer, GlaxoSmithKline, and Merck, among others.
Spain Atopic Dermatitis Therapeutics Market Analysis
The Spain Atopic Dermatitis Therapeutics Market was valued at US $237 Mn in 2022, and is predicted to grow at (CAGR) of 7.8% from 2023 to 2030, to US $433 Mn by 2030. The key drivers of this industry include a surge in the prevalence of Atopic Dermatitis (AD), increased awareness and diagnosis, and lifestyle modifications. The industry is primarily dominated by players such as Pfizer, Astellas, Novartis, Bayer, AbbVie, Viatris, Leo Pharma, and Regeneron, among others.
South Africa Atopic Dermatitis Therapeutics Market Analysis
The South Africa Atopic Dermatitis Therapeutics Market was valued at US $80 Mn in 2022, and is predicted to grow at (CAGR) of 10.03% from 2023 to 2030, to US $172 Mn by 2030. The key drivers of this industry include the increased burden of Atopic Dermatitis (AD), increasing government initiatives, and untapped market potential. The industry is primarily dominated by players such as Sanofi, Pfizer, Regeneron, Astellas, Novartis, Meda, and Allergan, among others.
Singapore Atopic Dermatitis Therapeutics Market Analysis
The Singapore Atopic Dermatitis Therapeutics Market was valued at US $15 Mn in 2022, and is predicted to grow at (CAGR) of 9.4% from 2023 to 2030, to US $30 Mn by 2030. The key drivers of this industry include the increased burden of Atopic Dermatitis (AD), strong healthcare infrastructure, supportive government policies, and others. The industry is primarily dominated by players such as Sanofi, Galderma, Merck, AbbVie, Glenmark, Novartis, and Johnson & Johnson, among others.
Saudi Arabia Atopic Dermatitis Therapeutics Market Analysis
The Saudi Arabia Atopic Dermatitis Therapeutics Market was valued at US $209 Mn in 2022, and is predicted to grow at (CAGR) of 10.3% from 2023 to 2030, to US $458 Mn by 2030. The key drivers of this industry include the rising prevalence of Atopic Dermatitis (AD), innovative drugs in the pipeline and evolving healthcare landscape. The industry is primarily dominated by players such as Sanofi, AbbVie, Pfizer, Regeneron, Eli Lilly, and Astellas, among others.
Philippines Atopic Dermatitis Therapeutics Market Analysis
The Philippines Atopic Dermatitis Therapeutics Market was valued at US $27 Mn in 2022, and is predicted to grow at (CAGR) of 9.3% from 2023 to 2030, to US $55 Mn by 2030. The key drivers of this industry include the rising prevalence of Atopic Dermatitis (AD), supportive government policies and improved socioeconomic conditions. The industry is primarily dominated by players such as UniLab, Pascual, Merck, Abbott, Bayer, Novartis, Johnson & Johnson, among others.
Mexico Atopic Dermatitis Therapeutics Market Analysis
The Mexico Atopic Dermatitis Therapeutics Market was valued at US $185 Mn in 2022, and is predicted to grow at (CAGR) of 9.05% from 2023 to 2030, to US $369 Mn by 2030. The key drivers of this industry include the upward trend in prevalence of Atopic Dermatitis (AD), supportive government policies and shifting treatment preferences. The industry is primarily dominated by players such as Sanofi, AbbVie, Pfizer, Bayer, GlaxoSmithKline, Merck among others.
Malaysia Atopic Dermatitis Therapeutics Market Analysis
The Malaysia Atopic Dermatitis Therapeutics Market was valued at US $20 Mn in 2022, and is predicted to grow at (CAGR) of 9% from 2023 to 2030, to US $39 Mn by 2030. The key drivers of this industry include increasing disease burden of Atopic Dermatitis (AD), supportive government policies, and technological advancements. The industry is primarily dominated by players such as Meda, Ivax, Pharmaniaga, Marufa, Sanofi, Novartis, Johnson & Johnson, and AbbVie among others.
Kenya Atopic Dermatitis Therapeutics Market Analysis
The Kenya Atopic Dermatitis Therapeutics Market was valued at US $9 Mn in 2022, and is predicted to grow at (CAGR) of 9.9% from 2023 to 2030, to US $18 Mn by 2030. The key drivers of this industry include the rising prevalence of Atopic Dermatitis (AD), emergence of novel therapeutic options, and others. The industry is primarily dominated by players such as Sanofi, Pfizer, AbbVie, Astellas, Novartis, Eli Lilly, Galderma, and Leo Pharma, among others.
Japan Atopic Dermatitis Therapeutics Market Analysis
The Japan Atopic Dermatitis Therapeutics Market was valued at US $77 Mn in 2022, and is predicted to grow at (CAGR) of 9.3% from 2023 to 2030, to US $1.56 Bn by 2030. The key drivers of this industry include the increasing disease burden of Atopic Dermatitis (AD), growing healthcare spending, and an evolving treatment landscape. The industry is primarily dominated by players such as Otsuka, Maruho, Tanabe, Fuji Film, Sanofi, Novartis, Mitsubishi, and AbbVie, among others.
Indonesia Atopic Dermatitis Therapeutics Market Analysis
The Indonesia Atopic Dermatitis Therapeutics Market was valued at US $74 Mn in 2022, and is predicted to grow at (CAGR) of 8.8% from 2023 to 2030, to US $145 Mn by 2030. The key drivers of this industry include the rising prevalence of Atopic Dermatitis (AD), growing disposable income and improved healthcare infrastructure. The industry is primarily dominated by players such as Sanofi, Novartis, Abbott, Merck, Roche, GSK, Bristol-Myers Squibb, among others.
Germany Atopic Dermatitis Therapeutics Market Analysis
The Germany Atopic Dermatitis Therapeutics Market was valued at US US $450 in 2022, and is predicted to grow at (CAGR) of 7.8% from 2023 to 2030, to US $773 Mn by 2030. The key drivers of this industry include the surge in prevalence of Atopic Dermatitis (AD), increased awareness and diagnosis and lifestyle modifications. The industry is primarily dominated by players such as Pfizer, Astellas, Novartis, Bayer, AbbVie, Viatris, Leo Pharma, and Regeneron, among others.
France Atopic Dermatitis Therapeutics Market Analysis
The France Atopic Dermatitis Therapeutics Market was valued at US $388 Mn in 2022, and is predicted to grow at (CAGR) of 7.80% from 2023 to 2030, to US $617 Mn by 2030. The key drivers of this industry include the upward trend in prevalence of Atopic Dermatitis (AD), emerging innovative therapeutics, and improved reimbursement policies. The industry is primarily dominated by players such as Sanofi, AbbVie, Viatris, Almirall, Leo Pharma, and Eli Lilly among others
Egypt Atopic Dermatitis Therapeutics Market Analysis
The Egypt Atopic Dermatitis Therapeutics Market was valued at US $34 Mn in 2022, and is predicted to grow at (CAGR) of 10.3% from 2023 to 2030, to US $75 Mn by 2030. The key drivers of this industry include the increased burden of Atopic Dermatitis (AD), improving healthcare infrastructure, adverse environmental conditions, and others. The industry is primarily dominated by players such as Sanofi, Pfizer, AstraZeneca, Abbott, Novartis, and Johnson & Johnson, among others.
China Atopic Dermatitis Therapeutics Market Analysis
The China Atopic Dermatitis Therapeutics Market was valued at US $0.99 Bn in 2022, and is predicted to grow at (CAGR) of 10.3% from 2023 to 2030, to US $2.16 Bn by 2030. The key drivers of this industry include a surge in the prevalence of Atopic Dermatitis (AD), emerging innovative therapeutics and increased awareness. The industry is primarily dominated by players such as Pfizer, Sanofi, Novartis, Galderma, AbbVie, Viatris, Bayer, and AstraZeneca, among others.
Canada Atopic Dermatitis Therapeutics Market Analysis
The Canada Atopic Dermatitis Therapeutics Market was valued at US $0.984 Bn in 2022, and is predicted to grow at (CAGR) of 8.8% from 2023 to 2030, to US $1.93 Bn by 2030. The key drivers of this industry include the rising prevalence of Atopic Dermatitis (AD), expansion in healthcare coverage and supportive government initiatives. The industry is primarily dominated by players such as Sanofi, AbbVie, Pfizer, Leo Pharma, Novartis among others.
